Investing.com - Nautilus Biotechnology (NASDAQ: NAUT) reported fourth quarter EPS of $-0.140, $0.02 better than the analyst estimate of $-0.160. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Nautilus Biotechnology's stock price closed at $2.940. It is up 0.340% in the last 3 months and up 33.720% in the last 12 months.
Nautilus Biotechnology saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Nautilus Biotechnology's stock price’s past reactions to earnings here.
According to InvestingPro, Nautilus Biotechnology's Financial Health score is "fair performance".
Check out Nautilus Biotechnology's recent earnings performance, and Nautilus Biotechnology's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar